230 related articles for article (PubMed ID: 23467237)
1. Metastasis awakening: the challenges of targeting minimal residual cancer.
Polzer B; Klein CA
Nat Med; 2013 Mar; 19(3):274-5. PubMed ID: 23467237
[No Abstract] [Full Text] [Related]
2. Metastasis awakening: targeting dormant cancer.
Aguirre-Ghiso JA; Bragado P; Sosa MS
Nat Med; 2013 Mar; 19(3):276-7. PubMed ID: 23467238
[No Abstract] [Full Text] [Related]
3. Immune dysfunction, minimal residual disease and patient outcome in nonmetastatic cancer: could modulation of immune function improve outcome?
Murray NP
Future Oncol; 2021 May; 17(13):1571-1575. PubMed ID: 33626930
[No Abstract] [Full Text] [Related]
4. Circulating Tumor Cells: Where From Here?
Datar RH; Balic M; Cote RJ
Semin Oncol; 2015 Aug; 42(4):515-7. PubMed ID: 26320056
[No Abstract] [Full Text] [Related]
5. Minimal residual neoplastic disease--concept, pathogenesis, and supplementary therapeutic possibilities.
Prindull G
Cancer Treat Rev; 1986 Sep; 13(3):177-94. PubMed ID: 3536089
[No Abstract] [Full Text] [Related]
6. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
[TBL] [Abstract][Full Text] [Related]
7. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
Mitra A; Mishra L; Li S
Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
[TBL] [Abstract][Full Text] [Related]
8. Cancer therapy: an evolved approach.
Willyard C
Nature; 2016 Apr; 532(7598):166-8. PubMed ID: 27075079
[No Abstract] [Full Text] [Related]
9. Minimal residual disease in cancer therapy--Small things make all the difference.
Blatter S; Rottenberg S
Drug Resist Updat; 2015; 21-22():1-10. PubMed ID: 26307504
[TBL] [Abstract][Full Text] [Related]
10. Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?
El Rassy E; Assi T; Kattan J
Future Oncol; 2017 Feb; 13(5):381-383. PubMed ID: 27884060
[No Abstract] [Full Text] [Related]
11. Micrometastatic disease in breast cancer: clinical implications.
Ignatiadis M; Georgoulias V; Mavroudis D
Eur J Cancer; 2008 Dec; 44(18):2726-36. PubMed ID: 19056036
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological strategies and micrometastasis: what is known? What must be done?
Perret GY
Minerva Med; 2010 Jun; 101(3):163-78. PubMed ID: 20562804
[TBL] [Abstract][Full Text] [Related]
13. Relevance of Minimal Residual Disease in the Era of Targeted Agents.
Heltai S; Ghia P; Scarfò L
Cancer J; 2019; 25(6):410-417. PubMed ID: 31764122
[TBL] [Abstract][Full Text] [Related]
14. Disseminated tumor cells: diagnosis, prognostic relevance, and phenotyping.
Pantel K; Otte M
Recent Results Cancer Res; 2001; 158():14-24. PubMed ID: 11092029
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells: highlight on practical implications.
Gazzaniga P; Raimondi C; Gradilone A; Naso G; Cortesi E; Frati L
Mol Diagn Ther; 2012 Feb; 16(1):7-11. PubMed ID: 22303967
[TBL] [Abstract][Full Text] [Related]
16. MRI in residual tumor size measurement in patient with breast cancer receiving neoadjuvant chemotherapy calls for caution.
Wu LM; Hu J; Xu JR
Breast Cancer Res Treat; 2012 Aug; 135(1):319-20. PubMed ID: 22850894
[No Abstract] [Full Text] [Related]
17. Apoptotic circulating tumor cells in early and metastatic breast cancer patients.
Kallergi G; Konstantinidis G; Markomanolaki H; Papadaki MA; Mavroudis D; Stournaras C; Georgoulias V; Agelaki S
Mol Cancer Ther; 2013 Sep; 12(9):1886-95. PubMed ID: 23778153
[TBL] [Abstract][Full Text] [Related]
18. Tumour microenvironment: informing on minimal residual disease in solid tumours.
Pantel K; Alix-Panabières C
Nat Rev Clin Oncol; 2017 Jun; 14(6):325-326. PubMed ID: 28397823
[No Abstract] [Full Text] [Related]
19. Minimal residual disease, the rationale for adjuvant therapy in epithelial malignancies.
Nissan A
J Surg Oncol; 2007 Sep; 96(3):185-7. PubMed ID: 17443732
[No Abstract] [Full Text] [Related]
20. Excisional surgery for cancer cure: therapy at a cost.
Coffey JC; Wang JH; Smith MJ; Bouchier-Hayes D; Cotter TG; Redmond HP
Lancet Oncol; 2003 Dec; 4(12):760-8. PubMed ID: 14662433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
